Financhill
Back

Replimune Group Quote, Financials, Valuation and Earnings

Sell
22

REPL
Replimune Group

Last Price:
6.43
Seasonality Move:
4.2%

7 Day Trial

ALL ACCESS PASS

$ 7

Replimune Group Price Quote

$6.43
-0.01 (-4.32%)
(Updated: May 18, 2024 at 5:52 AM ET)

Replimune Group Key Stats

Sell
22
Replimune Group (REPL) is a Sell

Day range:
$6.41 - $6.93
52-week range:
$5.86 - $24.81
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
1.06%

Volume:
901.5K
Avg. volume:
719.6K
1-year change:
-66.97%
Market cap:
$395.5M
Revenue:
$0
EPS:
$-3.24

How Much Does Replimune Group Make?

Data Unavailable

Is Replimune Group Growing As A Company?

Data Unavailable

Replimune Group Stock Price Performance

  • Did Replimune Group Stock Go Up Last Month?
    Replimune Group share price went down by -10.68% last month
  • Did REPL's Share Price Rise Over The Last Year?
    REPL share price fell by -66.97% over the past 1 year

What Is Replimune Group 52-Week High & Low?

Replimune Group Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Replimune Group?

  • How Much Debt Does Replimune Group Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Replimune Group Have?
    Cash and short term investments quarterly total is $420.7M
  • What Is Replimune Group’s Book Value Per Share?
    Book value per share is 6.10

Is Replimune Group Cash Flow Positive?

  • What Is REPL Cash Flow From Operations?
    Cash flow from operations (TTM) is -$185.5M
  • What Is Replimune Group’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $16.3M
  • What Is Replimune Group’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $97.2M

Replimune Group Return On Invested Capital

Data Unavailable

Replimune Group Earnings Date & Stock Price

Replimune Group Competitors

  • Who Are Replimune Group's Competitors?
    Below is a list of companies who compete with Replimune Group or are related in some way:
    • Esperion Therapeutics Inc (ESPR)
    • Gossamer Bio Inc (GOSS)
    • iBio Inc (IBIO)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)

Replimune Group Dividend Yield

Data Unavailable

Replimune Group Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 68.62%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 13.56
Upside from Last Price: 110.49%

Major Shareholders

  • How many REPL shares are owned by institutional investors?
    106M REPL shares are owned by institutional investors
  • How many REPL shares are owned by insiders?
    5.4M REPL shares are owned by insiders